Business
Next step of PathoQuest strategic collaboration
Next step of PathoQuest strategic collaboration.
About this update from Oxford Nanopore Technologies Plc
[{"type":"text","content":"\n\nOxford Nanopore and PathoQuest announce next step of strategic collaboration to bring to market the first sequencing-based quality control test for biopharma genetic characterisation and safety\n \nNanopore sequencing combined with PathoQuest expertise offers a new approach for biologics manufacturing with real-time, accurate testing for genetic characterisation, cutting months off traditional methods and providing more complete data.\n \nOXFORD, England and PARIS, France, 12 May 2023: Oxford Nanopore Technologies plc (LSE: ONT) (\"Oxford Nanopore\") and PathoQuest SAS today announce the signing of a definitive agreement to co-develop a transformational Integration Site Analysis (ISA) test to provide a Good Manufacturing Practice (GMP) validated nanopore sequencing-based commercial testing service to the biopharma industry. This is designed to address the needs of industrial developers and manufacturers of biological products, for example monoclonal antibodies or novel proteins that may be used across the life sciences/healthcare industry.\nOxford Nanopore's technology can read any length of native DNA with high accuracy, meaning that the technology can identify and comprehensively sequence gene insertion sites without the risk of missing off target integrations. In addition, the PathoQuest ISA test will leverage real-time data streaming, enabling rapid and accurate clone identification, with the potential to speed up biopharma manufacturing Quality Control (QC) testing by months over traditional methods and therefore to support faster or more effective outcomes for biopharma.\nBiologics manufacturing\nMost biologics, including monoclonal antibodies (mAbs) and recombinant proteins, are manufactured using genetically modified cell lines. For many cell therapies, the product itself is a genetically modified cell line. Throughout the development of these products, it is important to characterise and monitor the genetic modification(s) that have been made and assure the quality and safety of the product. Classical tests for this application have limitations in terms of scalability, speed and the completeness of data provided.\nThis brand-new test will allow sequencing of both the transgene and the genomic insertion site, overcoming the limitations of existing methodologies and delivering an accurate and rapid QC ...